Seres Therapeutics (MCRB) Announces New Phase 2 SER-109 Study in Patients with Multiply Recurrent C. Difficile

March 16, 2017 7:04 AM

Seres Therapeutics Inc., (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced plans to initiate a new SER-109 Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found